Solana Company SEC Filings

Fusion Summer Limited and CHEE Choon Wee disclosed a joint Schedule 13D reporting the acquisition of 6,830,402 shares of Helius Medical Technologies Class A common stock, representing 17.0% of the outstanding shares based on 40,295,612 shares. Fusion Summer paid approximately $47.0 million in a private placement (PIPE) that closed on September 18, 2025. Mr. CHEE, the ultimate controller of Fusion Summer, was appointed Executive Chairman effective at closing. The reporting persons hold shared voting and dispositive power over the shares and state the securities were acquired for investment purposes.

Helius Medical Technologies, Inc. filed an Form 8-K reporting corporate governance document updates effective September 29, 2025. The filing lists a Certificate of Amendment to the Certificate of Incorporation filed with Delaware on September 26, 2025 and effective September 29, 2025, a Third Amended and Restated Bylaws effective September 29, 2025, and a press release issued on September 29, 2025. The filing is signed by Jeffrey S. Mathiesen and includes an Inline XBRL cover page file.

Chee Choon Wee filed a Form 3 reporting initial beneficial ownership in Helius Medical Technologies, Inc. (HSDT). The filing shows 6,830,402 shares of common stock held indirectly through Fusion Summer Limited, 6,830,402 stapled warrants exercisable from 09/18/2025 for 36 months at a $10.134 exercise price, and 1,109,118 restricted stock units granted 09/18/2025, each convertible into one share under the companys 2022 Equity Incentive Plan.

Helius Medical Technologies reported new executive compensation arrangements and a key regulatory step for its neuromodulation device. The company entered into side letter agreements with President and CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen, granting one-time discretionary cash bonuses of $890,000 and $610,000, respectively. These cash bonuses will be offset dollar-for-dollar against any future severance, bonus, equity, retirement or other benefits the executives might otherwise receive under company plans or their employment agreements.

In return, both executives agreed that offerings completed on September 18, 2025 do not count as a change in control or trigger a good reason event under their employment agreements. Separately, Helius announced it has filed a U.S. FDA 510(k) submission seeking to expand the label for its Portable Neuromodulation Stimulator device to include gait and balance deficit in patients with chronic stroke symptoms, using data from its Stroke Registrational Program under its existing Breakthrough Device Designation.

Helius Medical Technologies, Inc. filed a current report to furnish information under Regulation FD. The company stated that on September 22, 2025 it issued a press release and attached this release as Exhibit 99.1 to the report. The filing does not describe the contents of the press release, instead directing readers to the attached exhibit for details.

Helius Medical Technologies completed a $500 million PIPE on September 18, 2025 and launched a Solana-centric digital asset treasury strategy to acquire SOL via open-market purchases and build Solana treasury operations. The PIPE included cash and cryptocurrency purchasers buying combinations of common shares, pre-funded warrants and stapled warrants; exercise of the cryptocurrency-related warrants is conditioned on stockholder approval. The company’s PoNS® portable neuromodulation device is cleared in the U.S. for short-term treatment of gait deficit due to mild-to-moderate MS, authorized in Canada for three indications and is Class IIa in Australia. Common stock trades on Nasdaq under HSDT (last reported price $23.17 on September 18, 2025) and there were 39,382,328 shares outstanding as of September 18, 2025.

Helius Medical Technologies detailed large private placements of stock and warrants that raised approximately $508.7 million in gross proceeds. The company sold 37,825,277 common shares, pre-funded warrants for 36,115,912 shares, and stapled warrants for 73,941,189 shares to accredited investors in cash and cryptocurrency offerings.

Helius plans to use the net proceeds mainly to acquire SOL, the native cryptocurrency of the Solana blockchain, and to build a Solana-based treasury operation, alongside general corporate purposes. Exercise of the cryptocurrency and advisor warrants, as well as vesting of certain RSUs, depends on stockholder approvals.

The filing also describes a new Master Loan Agreement for potential short-term SOL purchases, appointment of Joseph Chee as Executive Chairman with equity-based compensation tied to the offerings, amended indemnification agreements for directors and officers, and an increase in authorized common shares to 800,000,000 via a certificate of amendment.

Helius Medical Technologies entered a new sales agreement with Clear Street and Maxim Group that allows it to sell Class A common stock from time to time in an at-the-market offering with an aggregate sales price of up to $92.8 million under its existing shelf registration.

The agents will receive up to 3% of gross proceeds as commission, and the company agreed to reimburse up to $75,000 of certain legal expenses. Separately, stockholders approved increasing authorized common shares to 800,000,000, and the company plans to amend its certificate of incorporation to reflect this higher authorization.

Helius Medical Technologies filed a prospectus supplement for an at-the-market equity program to sell up to $92.8 million of Class A common stock and disclosed a contemporaneous PIPE (cash and cryptocurrency) and advisory agreements dated September 15, 2025. The company reported a last Nasdaq sale price of $7.56 per share and expects the PIPE to close on or about September 18, 2025, subject to customary conditions and stockholder approvals for certain warrants.

Management intends to use net proceeds primarily to acquire SOL (Solana) tokens and to support a Solana-centric digital asset treasury, with Pantera engaged as strategic and trading advisor. The filing discloses recent corporate actions including reverse stock splits, increases in authorized shares, prior private placements and Nasdaq compliance remediation; Nasdaq confirmed regained compliance but the company will be monitored until July 7, 2026. The supplement emphasizes significant regulatory, custody, staking and market risks tied to the Solana strategy and potential dilution from multiple warrant and financing arrangements.